Skip to main content

Table 6 Descriptive statistics of secondary outcome measured at baseline, 3 month, 9-month and 15-month after start of intervention and treatment effects as changes from baseline compared between groups

From: Is tailored treatment superior to non-tailored treatment for pain and disability in women with non-specific neck pain? A randomized controlled trial

Secondary Outcomes

TT

NTT

TAU

TT vs NTT

TT vs TAU

NTT vs TAU

Estimated mean (SD)

Estimated mean (SD)

Estimated mean (SD)

Effectsb (95 % CI)

Effectsb (95 % CI)

Effectsc (95 % CI)

ProFitMap intensity

 Baseline

71.64 (11.38)

71.55 (11.38)

70 (11.38)

   

 3 month

79.61 (11.02)

80.84 (11.16)

72.07 (11.07)

−1.31

(-3 to 5.62)

5.9

(1.51 to 10.29)**

7.21

(2.88 to 11.54)**

 9 month

78.48 (11.07)

81.49 (11.16)

75.91 (11.24)

−3.09

(-1.22 to 7.40)

0.92

(-3.49 to 5.33)

4.01

(-0.32 to 8.34)

 15 month

78.5 (11.02)

82.1 (11.22)

76.98 (11.18)

−3.67

(-0.64 to 7.98)

−0.13

(-4.48 to 4.22)

3.54

(-0.79 to 7.87)

ProFitMap frequency

 Baseline

66.02 (14.67)

67.74 (14.67)

64.08 (14.67)

   

 3 month

78.19 (14.05)

78.69 (14.22)

67.28 (14.16)

1.22

(-3.91 to 6.35)

8.97

(3.74 to 14.2)***

7.73

(2.56 to 12.9)**

 9 month

75.74 (14.05)

76.09 (14.28)

71.44 (14.25)

1.38

(-3.75 to 6.51)

2.36

(-2.85 to 7.57)

0.98

(-4.19 to 6.15)

 15 month

75.76 (14.05)

78.73 (14.34)

72.88 (14.25)

−1.24

(-6.41 to 3.9 )

0.95

(-4.26 to 3.61)

2.19

(-2.98 to 7.36)

PGICS

 3 month

2.20 (1.1)

2.19 (1.14)

3.64 (1.1)

0.01

(-0.52 to 0.54)

1.44

(0.9 to 1.98)***

1.45

(0.93 to 1.97)***

 9 month

2.5 (1.16)

2.53 (1.14)

3.13 (1.18)

0.04

(-0.49 to 0.57)

0.8

(0.31 to 1.29)**

0.85

(0.38 to 1.32)***

 15 month

2.49 (1.16)

2.47 (1.14)

3.18 (1.18)

−0.005

(-0.48 to 0.46)

0.75

(0.28 to 1.22)**

0.75

(0.28 to 1.22)**

PPT right

 Baseline

223.4 (102.7)

209.8 (102.8)

209.2 (102.8)

   

 3 month

251.6 (99.5)

237 (100.4)

203.3 (100.2)

1.03

(-38.4 to 40.4)

34.1

(-6.1 to 74.3)

33.06

(-6.6 to 72.8)

 9 month

251.5 (100.1)

263 (100.5)

228.4 (102.3)

−25.10

(-65.7 to 14.5)

8.92

(-31.4 to 49.3)

34.03

(-5.7 to 73.7)

PPT left

 Baseline

218.1 (95.8)

204.9 (95.8)

212.3 (95.8)

   

 3 month

247.6 (93.3)

223.4 (94.1)

197.3 (94.2)

11.01

(-28.8 to 50.9)

44.49

(3.7 to 85.2)*

33.47

(-6.6 to 73.6)

 9 month

244.8 (94.1)

243.7 (93.5)

224.6 (95.6)

−11.99

(-52.1 to 28.1)

14.46

(-26.3 to 55.2)

26.45

(-13.65 to 66.6)

Work Quantity

 Baselined

8.51 (1.58)

8.79 (1.58)

7.95 (1.51)

   

 3 month

9.23 (1.63)

9.15 (1.56)

8.91 (1.51)

0.36

(-0.46 to 1.18)

−0.25

(-1.07 to 0.57)

−0.61

(-1.47 to 0.19)

 9 month

9.58 (1.63)

9.24 (1.56)

8.94 (1.53)

0.62

(-0.2 to 1.44)

0.07

(-0.75 to 0.89)

−0.55

(-1.16 to 0.25)

 15 month

9.75 (1.63)

9.09 (1.56)

9.5 (1.53)

0.94

(0.12 to 1.76)*

−0.32

(-1.14 to 0.5)

−1.26

(-2.06 to -0.46)**

Work Quality

 Baselinee

7.43 (1.83)

8.32 (1.89)

7.53 (1.86)

   

 3 month

8.77 (1.86)

9.06 (1.8)

8.58 (1.74)

0.61

(-0.31 to 1.53)

0.28

(-0.64 to 1.2)

−0.32

(-1.22 to 0.58)

 9 month

9.18 (1.86)

9.0 (1.8)

8.52 (1.77)

1.08

(0.16 to 2)*

0.76

(-0.16 to 1.68)

−0.32

(-1.22 to 0.58)

 15 month

9.36 (1.86)

9.09 (1.8)

9.11 (1.77)

1.17

(0.25 to 2.09)*

0.34

(-0.58 to 1.26)

−0.82

(-1.72 to 0.08)

  1. TT tailored treatment group, NTT non-tailored treatment group, TAU treatment as usual group, vs versus, SD standard deviation, CI confidence interval; PGICS patient global impression of change scale, PPT pressure pain threshold; b Positive values of effects favor the tailored treatment group; c Positive values of effects favor the non-tailored treatment group; d TAU, significant lower (p < 0,05) than NT; e TT, significant lower (p < 0,05) than NTT; * comparison is significant at the 0,05 level, ** comparison is significant at the 0,01 level, *** comparison is significant at the 0,001 level